Clinical Trial Update: Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the WATCHMAN left atrial appendage occlusion device compared with rivaroxaban for patients with atrial fibrillation, focusing on stroke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Stroke

Drugs mentioned

• WATCHMAN Left Atrial Appendage Occlusion Device
• Xarelto (rivaroxaban)

Snippet

Sponsor: Shulin Wu | Conditions: Atrial Fibrillation, Stroke | Phase 4 | Status: UNKNOWN